Rechercher | MTSocial

Harshasharma Harshasharma Ajouter une nouvelle offre d'emploi Autre
2025-11-10 10:28:41 -

Trastuzumab Emtansine Market: A Precision Oncology Game-Changer on the Rise
The global trastuzumab emtansine market size was valued at USD 2.47 billion in 2024 and is expected to reach USD 4.78 billion by 2032, at a CAGR of 8.62% during the forecast period Introduction Trastuzumab emtansine is an antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent DM1 (a maytansine derivative) to HER2-positive cancer cells via the...

0 Commentaires 0 Parts 471 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
Harshasharma Harshasharma Ajouter une nouvelle offre d'emploi Networking
2025-12-01 07:43:05 -

Trastuzumab Emtansine Market: A Precision Oncology Game-Changer on the Rise
Targeted drug conjugates are reshaping cancer therapy, and trastuzumab emtansine (T-DM1, Kadcyla) stands at the forefront by combining antibody specificity with cytotoxic potency.This market analysis delves into growing demand, regulatory shifts, emerging indications, and competitive dynamics in the trastuzumab emtansine landscape. Introduction Trastuzumab emtansine is an antibody-drug...

0 Commentaires 0 Parts 254 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
Harshasharma Harshasharma Ajouter une nouvelle offre d'emploi Autre
2025-10-30 08:51:15 -

Trastuzumab Emtansine Market: A Precision Oncology Game-Changer on the Rise
The global trastuzumab emtansine market size was valued at USD 2.47 billion in 2024 and is expected to reach USD 4.78 billion by 2032, at a CAGR of 8.62% during the forecast period Introduction Trastuzumab emtansine is an antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent DM1 (a maytansine derivative) to HER2-positive cancer cells via the...

0 Commentaires 0 Parts 615 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
Harshasharma Harshasharma Ajouter une nouvelle offre d'emploi Autre
2025-10-15 09:09:41 -

Trastuzumab Emtansine Market: A Precision Oncology Game-Changer on the Rise
Targeted drug conjugates are reshaping cancer therapy, and trastuzumab emtansine (T-DM1, Kadcyla) stands at the forefront by combining antibody specificity with cytotoxic potency.This market analysis delves into growing demand, regulatory shifts, emerging indications, and competitive dynamics in the trastuzumab emtansine landscape. Introduction Trastuzumab emtansine is an antibody-drug...

0 Commentaires 0 Parts 694 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!